Arcutis files Form 144 to sell 1,341 vested shares

Arcutis Biotherapeutics filed a Form 144 notice reporting proposed disposition of 1,341 shares of Common Stock tied to Restricted Stock Vesting with an effective date of 05/01/2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics filed a Form 144 notice reporting proposed disposition of 1,341 shares of Common Stock tied to Restricted Stock Vesting with an effective date of 05/01/2026. The filing also lists a prior sale of 2,853 shares on 03/02/2026. The document names a broker (Merrill Lynch) and shows 124,033,382 shares outstanding as of 05/04/2026.

Key Figures

Proposed disposition: 1,341 shares Prior sale reported: 2,853 shares Shares outstanding: 124,033,382 shares +1 more

4 metrics

Proposed disposition 1,341 shares Restricted Stock Vesting on 05/01/2026

Prior sale reported 2,853 shares Sold during the past 3 months on 03/02/2026

Shares outstanding 124,033,382 shares as of 05/04/2026

Dollar figure shown 71,844.53 appears alongside the 2,853-share prior sale row

Key Terms

Restricted Stock Vesting, Form 144, Broker-dealer (Merrill Lynch)

3 terms

Restricted Stock Vesting financial

"Common | 05/01/2026 | Restricted Stock Vesting | Arcutis Biotherapeutics"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Form 144 regulatory

"CONTENT METADATA: "form_type": "144""

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Broker-dealer (Merrill Lynch) financial

"Common | Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Arcutis Biotherapeutics' (ARQT) Form 144 report?

It reports a proposed sale of 1,341 shares tied to restricted stock vesting. The filing shows the vesting date as 05/01/2026, names Merrill Lynch as the broker, and lists a prior sale of 2,853 shares on 03/02/2026.

How many shares did the filing show were previously sold for ARQT?

The filing lists a prior disposition of 2,853 shares on 03/02/2026. That prior sale appears in the "Securities Sold During The Past 3 Months" section with an associated figure of 71,844.53 shown in the same row of the excerpt.

Who is the broker listed in the ARQT Form 144 notice?

Merrill Lynch is named as the broker-dealer. The filing lists Merrill Lynch with an address at 8890 Lyra Drive, 5th Floor, Columbus OH 43240 in the securities section of the excerpt.

What is the shares outstanding figure shown in the filing for ARQT?

The excerpt shows 124,033,382 shares outstanding as of 05/04/2026. This number appears in the securities information row and is presented with the 05/04/2026 date in the excerpt.

What transaction type is associated with the 1,341 shares in the filing?

The 1,341 shares are associated with "Restricted Stock Vesting." The excerpt lists the securities type as Common and ties the 1,341-share entry to restricted stock vesting dated 05/01/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 05:18 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002065881
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Latha Vairavan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	1341	31661.81	124033382	05/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			1341	05/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Latha Vairavan 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	03/02/2026	2853	71844.53

144: Remarks and Signature

Remarks
Date of Notice	05/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Latha Vairavan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)